Should You Buy Boston Scientific Corp (BSX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BSX is a BUY right now for a beginner, long-term investor with $50k–$100k. The business is delivering strong growth (2025/Q3) and Wall Street remains broadly positive with ~$112 targets, while the stock has been pressured mainly by acquisition/slowdown fears. Even though the longer-term moving averages still look bearish and the price is sitting near a short-term resistance area (~94.20), the momentum indicators are improving (MACD turning up). With no Intellectia buy signal today, this is not a “must-buy today for a short-term trade,” but it is still a good long-term entry at current levels given the fundamental growth profile and supportive analyst stance.
Technical Analysis
Price/Trend: Mixed. Short-term momentum is improving, but the broader trend still leans bearish.
- MACD: Histogram 0.123 and expanding above 0 → bullish momentum building.
- RSI(6): 58.01 → neutral-to-slightly bullish (not overbought).
- Moving averages: Bearish stack (SMA_200 > SMA_20 > SMA_5) → longer-term trend still not fully recovered.
- Key levels: Pivot support ~91.25 (near-term line in the sand). Immediate resistance R1 ~94.20 (current price 94.06 is just below), then R2 ~96.02.
Interpretation: BSX is attempting a rebound, but it’s pressing into resistance; a clean break above ~94.20–96.00 would confirm improving trend. Downside risk is mainly a slip back toward ~91.25.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent trend: Still bullish overall, but with some price-target trimming.
- Goldman Sachs kept a Buy but cut PT to $112 from $124 (more conservative valuation assumptions).
- Evercore reiterated Outperform and added BSX to Tactical Outperform with a $112 PT, arguing recent fears are overdone.
- Several notes around Penumbra were downgrades of PEN (not BSX) due to the acquisition price, highlighting Street debate about deal valuation.
Wall Street pros: Durable medtech growth profile, improving fundamentals, and potential long-term M&A benefits.
Wall Street cons: Acquisition valuation/regulatory scrutiny and near-term headline risk (recall) can pressure sentiment and multiples.
Influential trading check (Congress, last 90 days): 8 total trades with 4 buys (median ~$3.3M) and 4 sells (median ~$0.8M) → activity is balanced, not a clear directional signal.
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 93.790
Current: 93.790
